WP
ACAD icon

Woodline Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Woodline Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1M Buy
+676,401
New +$16.2M 0.06% 403
2025
Q4 		– Sell
-151,453
Closed -$3.23M – 1011
2025
Q3 		$3.23M Sell
151,453
-685,746
-82% -$16.2M 0.02% 654
2025
Q2 		$18.1M Buy
837,199
+541,989
+184% +$10.1M 0.1% 309
2025
Q1 		$4.9M Buy
295,210
+268,445
+1,003% +$4.88M 0.03% 515
2024
Q4 		$491K Buy
+26,765
New +$432K ﹤0.01% 836
2024
Q1 		– Sell
-474,159
Closed -$14.8M – 530
2023
Q4 		$14.8M Buy
+474,159
New +$11.3M 0.16% 185
2023
Q3 		– Sell
-830,355
Closed -$19.9M – 582
2023
Q2 		$19.9M Buy
830,355
+399,450
+93% +$8.88M 0.24% 126
2023
Q1 		$8.11M Buy
+430,905
New +$8.21M 0.11% 227
2022
Q4 		– Sell
-395,549
Closed -$6.47M – 746
2022
Q3 		$6.47M Buy
395,549
+135,582
+52% +$2.2M 0.09% 253
2022
Q2 		$3.66M Buy
+259,967
New +$4.85M 0.06% 304
2022
Q1 		– Sell
-416,200
Closed -$9.71M – 711
2021
Q4 		$9.71M Sell
416,200
-172,659
-29% -$3.47M 0.14% 204
2021
Q3 		$9.78M Sell
588,859
-74,195
-11% -$1.43M 0.16% 166
2021
Q2 		$16.2M Buy
663,054
+272,463
+70% +$6.15M 0.3% 88
2021
Q1 		$10.1M Buy
390,591
+339,678
+667% +$15M 0.22% 116
2020
Q4 		$2.72M Sell
50,913
-276,502
-84% -$13.7M 0.07% 184
2020
Q3 		$13.5M Buy
327,415
+265,840
+432% +$11.5M 0.44% 68
2020
Q2 		$2.98M Buy
+61,575
New +$2.96M 0.12% 128

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Woodline Partners's ACAD Position: Q1 2026 in Review

Woodline Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 676,401 shares worth $15.1M. The stake represents 0.06% of the portfolio and ranks #403 among its holdings. This is a return to the name: Woodline Partners previously reported a position in ACAD as recently as Q3 2025.

Woodline Partners first reported a position in ACAD in Q2 2020 and has held it in 17 quarters since. The position peaked at $19.9M in Q2 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Woodline Partners held 676,401 shares of Acadia Pharmaceuticals worth $15.1M as of Q1 2026.
  • Acadia Pharmaceuticals was a new Woodline Partners position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.06% of Woodline Partners's portfolio in Q1 2026, its #403 holding.
  • Woodline Partners first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • Woodline Partners's Acadia Pharmaceuticals position peaked at $19.9M in Q2 2023.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.